Charlotte, N.C – Bourne Partners (“Bourne”), a leading financial services firm specializing in the pharma, pharma services, OTC and consumer health sectors announced today the appointment of Paul Campanelli, former CEO of Endo International plc as a senior advisor to the firm.

Paul is the former President, Chief Executive Officer and Director of Endo International with over 30 years of healthcare experience. Paul transformed the organization into an industry-leading generics business and built a strong leadership team with a vision of becoming a highly focused generics and specialty branded pharmaceutical company. Endo delivers quality medicines to patients in need through excellence in development, manufacturing, and commercialization in multiple business segments including U.S. Branded Pharmaceuticals, U.S. Branded Sterile Injectables, U.S. Generic Pharmaceuticals, and International Pharmaceuticals. Paul’s leadership drove the company to significantly increased total revenue.

During his tenure, Par and Endo acquired Michigan-based JHP Pharmaceuticals, established a business office in London to serve as Par’s entry point into the European generics market and completed its acquisition of an active pharmaceutical ingredients (API) facility located in Chennai, India. Paul also shaped the company’s strategic focus on organic growth through investments in hard-to-produce generic assets and technologies, a highly specialized branded business, and a concentration on differentiated and intelligent product selection. Earlier in his tenure, Paul served as Chief Operating Officer and President of Par Pharmaceutical, Inc., the company’s generics division, from 2011 to 2012. Mr. Campanelli also held roles of increasing responsibility, including Senior Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by Par’s board of directors. He served on the board of directors of Sky Growth Holdings Corporation.

“Paul is a long-time friend and industry colleague of our firm. He brings a great deal of knowledge and experience that will be invaluable to the continued growth and success of our business,” said Banks Bourne, Founder and CEO of Bourne Partners. “Paul’s contributions will help us as we continue to work together to carry out our company’s growth initiatives that include strategic acquisitions with Bourne Partners Strategic Capital, expanding our M&A advisory business and pipeline, and broadening the variety of services that we provide. We are looking forward to working together to ensure that the business continues to prosper.”

“I’ve known Banks and the team at Bourne Partners for quite some time and I am looking forward to the opportunity to work alongside them on some exciting new ventures. The company’s track record and reputation speak for themselves, and I am eager to see what more we can do together”, said Paul Campanelli.

Minor Hinson, Chief Investment Officer at BPSC commented, “We’ve known Paul for a long time and have had the pleasure of working with him on a number of transactions in the past. It is an exciting time for the firm, and we look forward to having Paul on board as we continue to grow both the private equity investment and investment banking businesses at Bourne.”

About Bourne Partners

Bourne Partners is a financial services firm specializing in the pharma, pharma services, OTC and consumer health sectors. Located in Charlotte, North Carolina, the company offers investment banking and advisory services.  Through Bourne Partners Strategic Capital (“BPSC”), Bourne invests and manages private equity investments in companies within the firm’s core focus areas. As owners and operators with over 20 years of experience, Bourne Partners strives to enrich the lives and improve the health and well-being of their partners and patients across the globe by facilitating the efficient movement of capital through the global healthcare sector. For more information, please visit www.bourne-partners.com.